Roche Licenses Rona Obesity Therapy in $1.16B Deal

Roche has licensed global rights to Rona Therapeutics' experimental obesity/metabolic therapy for up to $1.16 billion. The deal signals continued Big Pharma investment in next-generation obesity treatments, though the asset's clinical stage and differentiation remain undisclosed. This follows Roche's prior moves in the obesity space, reinforcing competitive pressure in a high-growth market.